市場調査レポート

商品コード

1442891

ヒトパピローマウイルスワクチン市場（適応症：子宮頸がん、肛門がん、膣がん、陰茎がん、外陰がん、中咽頭がん、性器いぼ、その他）世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Human Papillomavirus Vaccine Market (Indication: Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Oropharyngeal Cancer, Genital Warts, & Others) Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2031

出版日: 2024年01月04日 | 発行: Transparency Market Research

| ページ情報: 英文 212 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 5,795 910,626円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Multi-user License)

USD 8,795 1,382,046円

レポートPDFを同一の部署内・課内の方にご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

PDF (Corporate License)

USD 11,795 1,853,466円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は可能です。印刷物の取り扱いは電子版のライセンス範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

ヒトパピローマウイルスワクチン市場 - レポートの範囲

世界のヒトパピローマウイルスワクチン市場に関するTMRのレポートは、過去と現在の成長動向、および2023年から2031年の予測期間中に市場の指標の貴重な洞察を得る機会を研究しています。このレポートは、世界のヒトパピローマウイルスワクチンの収益を提供します2023年を基準年、2031年を予測年とみなして、2017年から2031年の期間の市場を分析します。レポートは、2023年から2031年までの世界のヒトパピローマウイルスワクチン市場の複合年間成長率（CAGR %）も提供します。

このレポートは広範な調査を経て作成されました。1次調査では、調査活動の大部分が行われ、アナリストが主要なオピニオンリーダー、業界リーダー、オピニオンメーカーにインタビューを実施しました。2次調査には、ヒトパピローマウイルスワクチン市場を理解するために、主要企業の製品文献、年次報告書、プレスリリース、および関連文書の参照が含まれます。

このレポートは、世界のヒトパピローマウイルスワクチン市場の競合情勢を詳しく掘り下げています。世界のヒトパピローマウイルスワクチン市場で活動する主要企業が特定され、これらのそれぞれがさまざまな属性の観点からプロファイルされています。会社概要、財務状況、最近の動向、 SWOTは、このレポートで紹介されている世界のヒトパピローマウイルスワクチン市場の企業の属性です。

市場企業 - 競争マトリックス（企業の階層および規模別）
市場シェア分析：企業別（2022年）
企業プロファイル
- Merck &Co., Inc.
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- Serum Institute of India Pvt. Ltd.
- Xiame Innovax Biotech Co., Ltd.
- General Incorporated Foundation
- The Chemo-Sero-Therapeutic Research Institute（Kaketsuken）
- Bharat Biotechare

図表

List of Tables

Table 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
Table 02: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 03: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 04: Global Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 05: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 06: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
Table 07: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 08: North America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 09: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 10: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
Table 11: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 12: Europe Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 13: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
Table 15: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 16: Asia Pacific Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 17: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 18: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
Table 19: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 20: Latin America Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
Table 21: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Valence, 2017-2031
Table 23: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Indication, 2017-2031
Table 24: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

Figure 01: Global Human Papillomavirus Vaccine Market Size (US$ Mn) and Distribution (%), by Region, 2017 and 2031
Figure 02: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Valence, 2022
Figure 03: Global Human Papillomavirus Vaccine Market Value Share, by Valence, 2022
Figure 04: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Indication, 2022
Figure 05: Global Human Papillomavirus Vaccine Market Value Share, by Indication, 2022
Figure 06: Global Human Papillomavirus Vaccine Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 07: Global Human Papillomavirus Vaccine Market Value Share, by Distribution Channel, 2022
Figure 08: Global Human Papillomavirus Vaccine Market Value Share, by Region, 2022
Figure 09: Global Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast, 2017-2031
Figure 10: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 11: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
Figure 12: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 13: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
Figure 14: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 15: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 16: Global Human Papillomavirus Vaccine Market Value Share Analysis, by Region, 2017 and 2031
Figure 17: Global Human Papillomavirus Vaccine Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 19: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country, 2023-2031
Figure 20: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Country, 2017 and 2031
Figure 21: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 22: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 23: North America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 24: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
Figure 25: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
Figure 26: North America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 27: Europe Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 28: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 29: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 30: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 31: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 32: Europe Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 33: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
Figure 34: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
Figure 35: Europe Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 36: Asia Pacific Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 37: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 38: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 39: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 40: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 41: Asia Pacific Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 42: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
Figure 43: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
Figure 44: Asia Pacific Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 45: Latin America Human Papillomavirus Vaccine Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 46: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 47: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 48: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 49: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 50: Latin America Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 51: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
Figure 52: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2023-2031
Figure 53: Latin America Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031
Figure 54: Middle East & Africa Human Papillomavirus Vaccine Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 55: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 56: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 57: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Valence, 2017 and 2031
Figure 58: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Indication, 2017 and 2031
Figure 59: Middle East & Africa Human Papillomavirus Vaccine Market Value Share Analysis, by Distribution Channel, 2017 and 2031
Figure 60: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Valence, 2023-2031
Figure 61: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Indication, 2022-2031
Figure 62: Middle East & Africa Human Papillomavirus Vaccine Market Attractiveness Analysis, by Distribution Channel, 2023-2031

Product Code: TMRGL37085

Human Papillomavirus Vaccine Market - Scope of Report

TMR's report on the global human papillomavirus vaccine market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global human papillomavirus vaccine market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global human papillomavirus vaccine market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the human papillomavirus vaccine market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global human papillomavirus vaccine market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global human papillomavirus vaccine market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global human papillomavirus vaccine market.

The report delves into the competitive landscape of the global human papillomavirus vaccine market. Key players operating in the global human papillomavirus vaccine market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global human papillomavirus vaccine market profiled in this report.

Key Questions Answered in Global human papillomavirus vaccine Market Report:

What is the sales/revenue generated by human papillomavirus vaccine across all regions during the forecast period?
What are the opportunities in the global human papillomavirus vaccine market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?

Human Papillomavirus Vaccine Market - Research Objectives and Research Approach

The comprehensive report on the global human papillomavirus vaccine market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global human papillomavirus vaccine market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global human papillomavirus vaccine market.

1. Preface

1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Papillomavirus Vaccine Market

4. Market Overview

4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
4.4. Global Human Papillomavirus Vaccine Market Analysis and Forecast, 2017-2031

5. Key Insights

5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry

6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence

6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Valence, 2017-2031
- 6.3.1. Bivalent
- 6.3.2. Quadrivalent and Nonavalent
6.4. Market Attractiveness Analysis, by Valence

7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication

7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Indication, 2017-2031
- 7.3.1. Cervical Cancer
- 7.3.2. Anal Cancer
- 7.3.3. Vaginal Cancer
- 7.3.4. Penile Cancer
- 7.3.5. Vulvar Cancer
- 7.3.6. Oropharyngeal Cancer
- 7.3.7. Genital Warts
- 7.3.8. Others
7.4. Market Attractiveness Analysis, by Indication

8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel

8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017-2031
- 8.3.1. Physicians
- 8.3.2. Wholesalers
- 8.3.3. Physician Distributors
- 8.3.4. Government Entities
- 8.3.5. Public and Private Alliances
8.4. Market Attractiveness Analysis, by Indication

9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region

9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
- 9.2.1. North America
- 9.2.2. Europe
- 9.2.3. Asia Pacific
- 9.2.4. Latin America
- 9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region

10. North America Human Papillomavirus Vaccine Market Analysis and Forecast

10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Valence, 2017-2031
- 10.3.1. Bivalent
- 10.3.2. Quadrivalent and Nonavalent
10.4. Market Value Forecast, by Indication, 2017-2031
- 10.4.1. Cervical Cancer
- 10.4.2. Anal Cancer
- 10.4.3. Vaginal Cancer
- 10.4.4. Penile Cancer
- 10.4.5. Vulvar Cancer
- 10.4.6. Oropharyngeal Cancer
- 10.4.7. Genital Warts
- 10.4.8. Others
10.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 10.5.1. Physicians
- 10.5.2. Wholesalers
- 10.5.3. Physician Distributors
- 10.5.4. Government Entities
- 10.5.5. Public and Private Alliances
10.6. Market Value Forecast, by Country, 2017-2031
- 10.6.1. U.S.
- 10.6.2. Canada
10.7. Market Attractiveness Analysis
- 10.7.1. By Valence
- 10.7.2. By Indication
- 10.7.3. By Distribution Channel
- 10.7.4. By Country

11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast

11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Valence, 2017-2031
- 11.3.1. Bivalent
- 11.3.2. Quadrivalent and Nonavalent
11.4. Market Value Forecast, by Indication, 2017-2031
- 11.4.1. Cervical Cancer
- 11.4.2. Anal Cancer
- 11.4.3. Vaginal Cancer
- 11.4.4. Penile Cancer
- 11.4.5. Vulvar Cancer
- 11.4.6. Oropharyngeal Cancer
- 11.4.7. Genital Warts
- 11.4.8. Others
11.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 11.5.1. Physicians
- 11.5.2. Wholesalers
- 11.5.3. Physician Distributors
- 11.5.4. Government Entities
- 11.5.5. Public and Private Alliances
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 11.6.1. Germany
- 11.6.2. U.K.
- 11.6.3. France
- 11.6.4. Italy
- 11.6.5. Spain
- 11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
- 11.7.1. By Valence
- 11.7.2. By Indication
- 11.7.3. By Distribution Channel
- 11.7.4. By Country/Sub-region

12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast

12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Valence, 2017-2031
- 12.3.1. Bivalent
- 12.3.2. Quadrivalent and Nonavalent
12.4. Market Value Forecast, by Indication, 2017-2031
- 12.4.1. Cervical Cancer
- 12.4.2. Anal Cancer
- 12.4.3. Vaginal Cancer
- 12.4.4. Penile Cancer
- 12.4.5. Vulvar Cancer
- 12.4.6. Oropharyngeal Cancer
- 12.4.7. Genital Warts
- 12.4.8. Others
12.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 12.5.1. Physicians
- 12.5.2. Wholesalers
- 12.5.3. Physician Distributors
- 12.5.4. Government Entities
- 12.5.5. Public and Private Alliances
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 12.6.1. China
- 12.6.2. Japan
- 12.6.3. India
- 12.6.4. Australia & New Zealand
- 12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
- 12.7.1. By Valence
- 12.7.2. By Indication
- 12.7.3. By Distribution Channel
- 12.7.4. By Country/Sub-region

13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast

13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Valence, 2017-2031
- 13.3.1. Bivalent
- 13.3.2. Quadrivalent and Nonavalent
13.4. Market Value Forecast, by Indication, 2017-2031
- 13.4.1. Cervical Cancer
- 13.4.2. Anal Cancer
- 13.4.3. Vaginal Cancer
- 13.4.4. Penile Cancer
- 13.4.5. Vulvar Cancer
- 13.4.6. Oropharyngeal Cancer
- 13.4.7. Genital Warts
- 13.4.8. Others
13.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 13.5.1. Physicians
- 13.5.2. Wholesalers
- 13.5.3. Physician Distributors
- 13.5.4. Government Entities
- 13.5.5. Public and Private Alliances
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 13.6.1. Brazil
- 13.6.2. Mexico
- 13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
- 13.7.1. By Valence
- 13.7.2. By Indication
- 13.7.3. By Distribution Channel
- 13.7.4. By Country/Sub-region

14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast

14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Valence, 2017-2031
- 14.3.1. Bivalent
- 14.3.2. Quadrivalent and Nonavalent
14.4. Market Value Forecast, by Indication, 2017-2031
- 14.4.1. Cervical Cancer
- 14.4.2. Anal Cancer
- 14.4.3. Vaginal Cancer
- 14.4.4. Penile Cancer
- 14.4.5. Vulvar Cancer
- 14.4.6. Oropharyngeal Cancer
- 14.4.7. Genital Warts
- 14.4.8. Others
14.5. Market Value Forecast, by Distribution Channel, 2017-2031
- 14.5.1. Physicians
- 14.5.2. Wholesalers
- 14.5.3. Physician Distributors
- 14.5.4. Government Entities
- 14.5.5. Public and Private Alliances
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
- 14.6.1. GCC Countries
- 14.6.2. South Africa
- 14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
- 14.7.1. By Valence
- 14.7.2. By Indication
- 14.7.3. By Distribution Channel
- 14.7.4. By Country/Sub-region

15. Competition Landscape

15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
- 15.3.1. Merck & Co., Inc.
  - 15.3.1.1. Company Overview
  - 15.3.1.2. Product Portfolio
  - 15.3.1.3. SWOT Analysis
  - 15.3.1.4. Financial Overview
  - 15.3.1.5. Strategic Overview
- 15.3.2. GlaxoSmithKline plc
  - 15.3.2.1. Company Overview
  - 15.3.2.2. Product Portfolio
  - 15.3.2.3. SWOT Analysis
  - 15.3.2.4. Financial Overview
  - 15.3.2.5. Strategic Overview
- 15.3.3. Sanofi
  - 15.3.3.1. Company Overview
  - 15.3.3.2. Product Portfolio
  - 15.3.3.3. SWOT Analysis
  - 15.3.3.4. Financial Overview
  - 15.3.3.5. Strategic Overview
- 15.3.4. AstraZeneca
  - 15.3.4.1. Company Overview
  - 15.3.4.2. Product Portfolio
  - 15.3.4.3. SWOT Analysis
  - 15.3.4.4. Financial Overview
  - 15.3.4.5. Strategic Overview
- 15.3.5. Serum Institute of India Pvt. Ltd.
  - 15.3.5.1. Company Overview
  - 15.3.5.2. Product Portfolio
  - 15.3.5.3. SWOT Analysis
  - 15.3.5.4. Financial Overview
  - 15.3.5.5. Strategic Overview
- 15.3.6. Xiame Innovax Biotech Co., Ltd.
  - 15.3.6.1. Company Overview
  - 15.3.6.2. Product Portfolio
  - 15.3.6.3. SWOT Analysis
  - 15.3.6.4. Financial Overview
  - 15.3.6.5. Strategic Overview
- 15.3.7. General Incorporated Foundation
  - 15.3.7.1. Company Overview
  - 15.3.7.2. Product Portfolio
  - 15.3.7.3. SWOT Analysis
  - 15.3.7.4. Financial Overview
  - 15.3.7.5. Strategic Overview
- 15.3.8. The Chemo-Sero-Therapeutic Research Institute (Kaketsuken)
  - 15.3.8.1. Company Overview
  - 15.3.8.2. Product Portfolio
  - 15.3.8.3. SWOT Analysis
  - 15.3.8.4. Financial Overview
  - 15.3.8.5. Strategic Overview
- 15.3.9. Bharat Biotechare
  - 15.3.9.1. Company Overview
  - 15.3.9.2. Product Portfolio
  - 15.3.9.3. SWOT Analysis
  - 15.3.9.4. Financial Overview
  - 15.3.9.5. Strategic Overview

ヒトパピローマウイルスワクチン市場（適応症：子宮頸がん、肛門がん、膣がん、陰茎がん、外陰がん、中咽頭がん、性器いぼ、その他）世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Human Papillomavirus Vaccine Market (Indication: Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Oropharyngeal Cancer, Genital Warts, & Others) Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2031

ヒトパピローマウイルスワクチン市場 - レポートの範囲

目次

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界市場

第4章市場概要

第5章重要な洞察

第6章世界市場の分析と予測：価数別

第7章世界市場の分析と予測：適応症別

第8章世界市場の分析と予測：流通チャネル別

第9章世界市場の分析と予測：地域別

第10章北米市場の分析と予測

第11章欧州市場の分析と予測

第12章アジア太平洋市場の分析と予測

第13章ラテンアメリカ市場の分析と予測

第14章中東・アフリカ市場の分析と予測

第15章競合情勢

List of Tables

List of Figures

Human Papillomavirus Vaccine Market - Scope of Report

Key Questions Answered in Global human papillomavirus vaccine Market Report:

Human Papillomavirus Vaccine Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Papillomavirus Vaccine Market

4. Market Overview

5. Key Insights

6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence

7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication

8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel

9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region

10. North America Human Papillomavirus Vaccine Market Analysis and Forecast

11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast

12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast

13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast

14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast

15. Competition Landscape

ヒトパピローマウイルスワクチン市場（適応症：子宮頸がん、肛門がん、膣がん、陰茎がん、外陰がん、中咽頭がん、性器いぼ、その他）世界の業界分析、規模、シェア、成長、動向、および予測、2023年～2031年

Human Papillomavirus Vaccine Market (Indication: Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Oropharyngeal Cancer, Genital Warts, & Others) Global Industry Analysis, Size, Share, Growth, Trends, & Forecast, 2023-2031

ヒトパピローマウイルスワクチン市場 - レポートの範囲

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

第5章 重要な洞察

第6章 世界市場の分析と予測：価数別

第7章 世界市場の分析と予測：適応症別

第8章 世界市場の分析と予測：流通チャネル別

第9章 世界市場の分析と予測：地域別

第10章 北米市場の分析と予測

第11章 欧州市場の分析と予測

第12章 アジア太平洋市場の分析と予測

第13章 ラテンアメリカ市場の分析と予測

第14章 中東・アフリカ市場の分析と予測

第15章 競合情勢

List of Tables

List of Figures

Human Papillomavirus Vaccine Market - Scope of Report

Key Questions Answered in Global human papillomavirus vaccine Market Report:

Human Papillomavirus Vaccine Market - Research Objectives and Research Approach

Table of Contents

1. Preface

2. Assumptions and Research Methodology

3. Executive Summary: Global Human Papillomavirus Vaccine Market

4. Market Overview

5. Key Insights

6. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Valence

7. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Indication

8. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Distribution Channel

9. Global Human Papillomavirus Vaccine Market Analysis and Forecast, by Region

10. North America Human Papillomavirus Vaccine Market Analysis and Forecast

11. Europe Human Papillomavirus Vaccine Market Analysis and Forecast

12. Asia Pacific Human Papillomavirus Vaccine Market Analysis and Forecast

13. Latin America Human Papillomavirus Vaccine Market Analysis and Forecast

14. Middle East & Africa Human Papillomavirus Vaccine Market Analysis and Forecast

15. Competition Landscape

第1章序文

第2章前提条件と調査手法

第3章エグゼクティブサマリー：世界市場

第4章市場概要

第5章重要な洞察

第6章世界市場の分析と予測：価数別

第7章世界市場の分析と予測：適応症別

第8章世界市場の分析と予測：流通チャネル別

第9章世界市場の分析と予測：地域別

第10章北米市場の分析と予測

第11章欧州市場の分析と予測

第12章アジア太平洋市場の分析と予測

第13章ラテンアメリカ市場の分析と予測

第14章中東・アフリカ市場の分析と予測

第15章競合情勢